Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from extravascular spaces (e.g., brain, eyes) into the intravascular compartment and enhancing water excretion by the kidneys. Dextrose provides caloric supplementation, and sodium chloride provides electrolytes to maintain tonicity.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Reduction of intracranial pressure (FDA-approved for cerebral edema),Reduction of intraocular pressure in acute glaucoma,Promotion of diuresis in drug overdose (e.g., barbiturates, salicylates),Osmotic diuresis in acute renal failure prevention (e.g., during cardiovascular surgery),Adjuvant in urology for bladder irrigation (off-label),Prevention of acute kidney injury in rhabdomyolysis (off-label)
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion. For osmotic diuresis: 50-100 g (1000-2000 m L of this solution) over 1-2 hours, total dose not exceeding 200 g/day. For reduction of intracranial pressure: 1.5-2 g/kg as a 20-25% solution given IV over 30-60 minutes. This 5% solution is not typically used for ICP reduction due to dilution.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Mannitol: 0.25–1.5 hours (approximately 15–90 minutes); prolonged in renal impairment. Dextrose: <30 minutes (endogenous regulation).
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Mannitol is not significantly metabolized; it is freely filtered by the glomeruli and excreted unchanged in urine. Dextrose is metabolized via glycolysis and oxidative phosphorylation. Sodium chloride dissociates into ions that are handled by renal tubular transport.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: >90% mannitol excreted unchanged in urine; dextrose is fully reabsorbed or metabolized; sodium chloride is handled by renal tubules.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Mannitol: 0% (not bound); dextrose: negligible; sodium: minimal.
Low protein binding; 0–11% bound, primarily to albumin.
Mannitol: ~0.3–0.7 L/kg; distributes primarily in extracellular fluid; does not cross cell membranes significantly.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100% for all components.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Contraindicated in anuria due to severe renal disease or severe renal impairment (GFR <10 m L/min). Caution in mild to moderate impairment; monitor serum osmolality and electrolytes. No specific GFR-based dose adjustment established.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific adjustment for Child-Pugh class. Caution in severe hepatic impairment due to risk of fluid overload and electrolyte disturbances.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
For osmotic diuresis: 2 g/kg IV over 1-2 hours as a 15-20% solution. For cerebral edema: 1-2 g/kg IV over 30-60 minutes as a 20-25% solution. Not typically using this 5% formulation for these indications.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Use with caution due to age-related decline in renal function. Monitor renal function, fluid balance, and electrolytes. Initiate at low end of dosing range.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
May cause circulatory overload, pulmonary edema, or congestive heart failure in patients with compromised cardiac function. Monitor serum electrolytes, osmolality, and renal function. Use with caution in patients with anuria, severe renal impairment, or active intracranial bleeding (risk of expansion). Avoid extravasation (can cause tissue necrosis). Rapid administration may cause headache, nausea, or blurred vision.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Anuria (due to severe renal disease), pulmonary edema (due to fluid overload), active intracranial bleeding (unless during craniotomy), severe dehydration, established acute tubular necrosis (use may worsen), hypersensitivity to any component.
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions. However, avoid high-sodium foods to prevent exacerbation of hypernatremia.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Pregnancy Category C. Mannitol and dextrose combinations are generally considered low risk for teratogenicity. Mannitol is an osmotic diuretic that does not cross the placenta significantly at therapeutic doses. Dextrose is a normal constituent of maternal and fetal blood; however, hyperglycemia from dextrose infusion may be associated with fetal hyperinsulinism and macrosomia if maternal glucose is poorly controlled. No specific teratogenic effects have been reported for this combination. Benefit-risk assessment is required.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Mannitol and dextrose are endogenous substances or metabolites. Mannitol is excreted into breast milk in small amounts (M/P ratio unknown but likely low due to high molecular weight). Dextrose is a normal milk component. I. V. administration may raise maternal blood glucose, but effects on infant are minimal at therapeutic doses. Caution in lactation due to potential for maternal hyperglycemia.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Due to increased plasma volume (50% increase) and glomerular filtration rate (50-60% increase) in pregnancy, clearance of mannitol and dextrose may be enhanced. Monitor serum osmolarity and electrolytes; adjust infusion rate to avoid hyperosmolarity or fluid overload. No specific dose reduction required but careful titration is recommended. Blood glucose monitoring is essential to avoid maternal hyperglycemia.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Monitor serum sodium and osmolality closely due to risk of hypernatremia and hyperosmolality; contraindicated in anuria, severe pulmonary edema, and intracranial hemorrhage. Use with caution in patients with renal impairment or congestive heart failure.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Report any swelling, shortness of breath, or rapid weight gain.,Do not consume additional salt in diet while receiving this infusion.,Inform healthcare provider if you have kidney problems or heart failure.,This medication may cause increased urination; keep track of fluid intake and output.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% is a Electrolyte that works by Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from extravascular spaces (e.g., brain, eyes) into the intravascular compartment and enhancing water excretion by the kidneys. Dextrose provides caloric supplementation, and sodium chloride provides electrolytes to maintain tonicity.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% is: Intravenous infusion. For osmotic diuresis: 50-100 g (1000-2000 m L of this solution) over 1-2 hours, total dose not exceeding 200 g/day. For reduction of intracranial pressure: 1.5-2 g/kg as a 20-25% solution given IV over 30-60 minutes. This 5% solution is not typically used for ICP reduction due to dilution.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% is classified as Category A/B. Pregnancy Category C. Mannitol and dextrose combinations are generally considered low risk for teratogenicity. Mannitol is an osmotic diuretic that does not cross the placenta sign. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.